Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

PR Newswire

BOULDER, Colo., March 4, 2026

BOULDER, Colo. , March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET.

Edgewise Therapeutics (PRNewsfoto/Edgewise Therapeutics)

The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page  and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to  edgewisetx.com or follow us on  LinkedInXFacebook and  Instagram .

Cision
View original content to download multimedia: https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-leerink-global-healthcare-conference-on-march-11-2026-302699637.html

SOURCE Edgewise Therapeutics

Läs mer på PR Newswire

Ämnen i artikeln

Edgewise Therapeutics

Senast

29,06

1 dag %

−3,29%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån